And that Amgen did 20 Billion in revenue in 2014? The math is pretty simple. Evolocumab is about to make Amgen some serious cash. Looking forward to Thursday's Approval by the FDA.
Doctors out of NYU Langone are seeing unbelievable results in clinic with evolocumab. Probably the best thing to come along since Liptor for the management of hypocholesterolemia. Give us approval this week, and let's see 200+ over the coming months. Amgen will get the pricing structure right.
Take a look at the accumulation/distribution chart for the past few weeks. Also noticed that Barron's suggested them as a takeout target for CUDC-907.
I'm not sure what, but there are some subtle signs that it'll be moving higher. Can't place my finger on why, I don't see it being the result of some near term drug milestone, rather it has to be something strategic in the works. It's definitely signaling a move higher, I just wish I could identify a catalyst, as I'm hesitant to place more money to work.
Filed 8/13. Interesting...
"Larger companies are also in the hunt for a vaccine against RSV. GlaxoSmithKline Plc is studying a vaccine to prevent the disease in children, as is AstraZeneca Plc’s Medimmune business. Medimmune already produces a drug to prevent lung disease caused by RSV in children."
TTPH probably is acquired first, though I think on the lower range $95-$120. CEMP happens second, for a higher premium due the wider indications for solithromycin. I do think it's safe to say that consolidation in the antibiotic space will happen it's just a question of when. Particularly with the FDA's push to bring new antibiotics to market.
Institutional ownership is non existent, PR appears to be puff pieces. PolyMedix went bankrupt trying to get approval for Brilacidin. Purisol was supposed to be some great cure for Psoriasis yet there have been no updates. The market cap here is crazy. Oh and their cash position is troublesome. Without more dilution I don't see how this continues.